Danese, ElisaRaimondi, SaraMontagnana, MartinaTagetti, AngelaLangaee, TaimourBorgiani, PaolaCiccacci, CinziaCarcas, Antonio JBorobia, Alberto MTong, Hoi YDávila-Fajardo, CristinaRodrigues Botton, MarianaBourgeois, StephaneDeloukas, PanosCaldwell, Michael DBurmester, Jim KBerg, Richard LCavallari, Larisa HDrozda, KatarzynaHuang, MinZhao, Li-ZiCen, Han-JingGonzalez-Conejero, RocioRoldan, VanessaNakamura, YusukeMushiroda, TaiseiGong, Inna YKim, Richard BHirai, KeitaItoh, KunihikoIsaza, CarlosBeltrán, LeonardoJiménez-Varo, EnriqueCañadas-Garre, MarisaGiontella, AliceKringen, Marianne KHaug, Kari Bente FossGwak, Hye SunLee, Kyung EunMinuz, PietroLee, Ming Ta MichaelLubitz, Steven AScott, StuartMazzaccara, CristinaSacchetti, LuciaGenç, EceÖzer, MahmutPathare, AnilKrishnamoorthy, RajagopalPaldi, AndrasSiguret, VirginieLoriot, Marie-AnneKutala, Vijay KumarSuarez-Kurtz, GuilhermePerini, JamilaDenny, Josh CRamirez, Andrea HMittal, BalrajRathore, Saurabh SinghSagreiya, HershAltman, RussShahin, Mohamed Hossam AKhalifa, Sherief ILimdi, Nita ARivers, CharlesShendre, AditiDillon, ChrislySuriapranata, Ivet MZhou, Hong-HaoTan, Sheng-LanTatarunas, VacisLesauskaite, VaivaZhang, YumaoMaitland-van der Zee, Anke HVerhoef, Talitha Ide Boer, AnthoniusTaljaard, MonicaZambon, Carlo FedericoPengo, VittorioZhang, Jieying EunicePirmohamed, MunirJohnson, Julie AFava, Cristiano2023-01-252023-01-252019-02-17http://hdl.handle.net/10668/13273The cytochrome P450 (CYP)4F2 gene is known to influence mean coumarin dose. The aim of the present study was to undertake a meta-analysis at the individual patients level to capture the possible effect of ethnicity, gene-gene interaction, or other drugs on the association and to verify if inclusion of CYP4F2*3 variant into dosing algorithms improves the prediction of mean coumarin dose. We asked the authors of our previous meta-analysis (30 articles) and of 38 new articles retrieved by a systematic review to send us individual patients' data. The final collection consists of 15,754 patients split into a derivation and validation cohort. The CYP4F2*3 polymorphism was consistently associated with an increase in mean coumarin dose (+9% (95% confidence interval (CI) 7-10%), with a higher effect in women, in patients taking acenocoumarol, and in white patients. The inclusion of the CYP4F2*3 in dosing algorithms slightly improved the prediction of stable coumarin dose. New pharmacogenetic equations potentially useful for clinical practice were derived.enAgedAged, 80 and overCohort StudiesCoumarinsCytochrome P-450 CYP2C9Cytochrome P450 Family 4Dose-Response Relationship, DrugFemaleHumansMaleMiddle AgedPolymorphism, Single NucleotideVitamin K Epoxide Reductasesresearch article30506689open access10.1002/cpt.13231532-6535PMC6542461https://europepmc.org/articles/pmc6542461?pdf=renderhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6542461/pdf